Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD

https://doi.org/10.17749/2070-4909.2017.10.2.031-040

Full Text:

Abstract

In accordance with currently accepted recommendations for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), both monotherapy with long-acting anticholinergics (LAAC) or combined therapy (LAAC / long-acting beta-agonists, LABA) can be used. To justify a rational choice between these two medications, we used the methodology of clinical/economic analysis.

Objective: to assess possible financial and clinical/economic consequences of replacing monotherapy based on LAAC (tiotropium bromide) by the fixed combination of LAAC / LABA (vilantererol / umeclidinum bromide) in patients with severe and extremely severe COPD.

Materials and methods. The target population included patients with severe and extremely severe COPD (FEV1 <50%, CAT ≥10, mMRC ≥2, with severe symptoms). QALY (quality-adjusted life-year) was used as the main criterion of effectiveness. Direct medical costs of drug therapy, and the costs of management of adverse events and/or COPD exacerbations were calculated. The costs of these two therapeutic regimens were calculated from the registered data on the maximum selling prices of VED drugs or from the prices expected if/when the given drugs are registered in the VED list (+ VAT + weighted average wholesale premium). Other direct medical costs were calculated in accordance with the Federal program of free medical care, as well as the cost-effectiveness factors recommended by the FFOMS. The obtained values of savings in direct medical costs and the cost-effectiveness ratio (CER) were evaluated for their sensitivity to changes in basic prices of the compared medications.

Results. The use of vilantererol / umeclidinum bromide resulted in improved lung function (an increase in FEV1 by 120% on the 169th day, 0.205 vs 0.093), improved quality of life and reduced symptoms, as well as a 63%-lower need for urgent drugs as compared to the tiotropium bromide monotherapy. The quality of life was 0.752 and 0.732 QALY in the group of vilantererol / umeclidinum bromide and tiotropium bromide, respectively. The direct medical costs in these two groups amounted to 32,753 rubles and 37,641 rubles, respectively. Thus, the savings of using the combined medication reached 4,888 rubles, which is 13% less than that with the mono-component drug. If the current practice of treating COPD with tiotropium bromide is replaced by the combined vilantererol / umeclidinum therapy, the total budget savings can reach more than 327 million rubles.

Conclusion. The use of vilantererol/umeclidinum for the treatment of severe and extremely severe COPD is strongly preferred over tiotropium bromide, as it leads to significantly better clinical outcomes and provides savings for the health care budget. 

About the Authors

E. G. Kosolapov
Independent Research Company «Smart Choice»
Russian Federation
Otkrytoe shosse, 23/6, Moscow, 107143


F. S. Kochenkov
Independent Research Company «Smart Choice»
Russian Federation
Otkrytoe shosse, 23/6, Moscow, 107143


N. L. Pogudina
Independent Research Company «Smart Choice»
Russian Federation

PhD,

Otkrytoe shosse, 23/6, Moscow, 117997



D. V. Blinov
N.I. Pirogov Russian National Research Medical University
Russian Federation

PhD, 

ul. Ostrovityanova, 1, Moscow, 117997



References

1. Ovcharenko S. I. Lechebnoe Delo. 2004; 2: 24-30.

2. Gershon A. S. et al. Forecasting Health Services Use In Individuals With Chronic Obstructive Pulmonary Disease (COPD): A Time-Series Analysis //C96. Global Perspectives on COPD Burden and Care Delivery. American Thoracic Society. 2016; A6159-A6159.

3. Mannino D. M. et al. Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013. International Journal of COPD. 2014; 9: 597-611.

4. Crighton E. J. et al. A spatial analysis of COPD prevalence, incidence, mortality and health service use in Ontario. Health reports. 2015; 26 (3): 10.

5. Evans J. et al. Estimating the prevalence of COPD in Canada: Reported diagnosis versus measured airflow obstruction. Health reports. 2014; 25 (3): 3.

6. Gaigol’nik T. V., Demko I. V., Bochanova E. N., Kraposhina A. Yu., Gordeeva N. V., Solov’eva I. A. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2016; 2: 49-59. DOI: 10.17749/2070-4909.2016.9.2.049-059.

7. Doklad VOZ. Khronicheskaya obstruktivnaya bolezn’ legkikh (KhOBL): Informatsionnyi byulleten’ №315, 2015. URL: http://www.who.int/mediacentre/factsheets/fs315/ru/. Accessed: 28.12.2016.

8. Vidyakina E. E., Mal’chikova S. V. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2016; 2: 45-48. DOI: 10.17749/2070-4909.2016.9.2.045-048.

9. Chuchalin A. G. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of Chronic Obstructive Pulmonary Disease. 2014; 9: 963-974.

10. Aleksandrova G. A., Polikarpov A. V., Golubev N. A. et al. The incidence of the entire population of Russia in 2015. Statistical materials. Part I [Zabolevaemost’ vsego naseleniya Rossii v 2015 godu. Statisticheskie materialy. Chast’ I (in Russian)]. Moscow. 2016; 139 s.

11. Aleksandrova G. A., Polikarpov A. V., Golubev N. A. s soavt. The incidence of the entire population of Russia in 2015. Statistical materials. Part II [Zabolevaemost’ vsego naseleniya Rossii v 2015 godu. Statisticheskie materialy. Chast’ II (in Russian)]. Moscow. 2016; 141 s.

12. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. URL: http://goldcopd.org. Accessed: 17.03.2017.

13. Omel’yanovskii V. V., Avksent’eva M. V., Sura M. V., Gerasimova K. V., Dzanaeva A. V. Methodical recommendations for conducting a comparative clinical and economic evaluation of a medicinal product [Metodicheskie rekomendatsii po provedeniyu sravnitel’noi kliniko-ekonomicheskoi otsenki lekarstvennogo preparata (in Russian)]. Moscow. 2016; 20 s.

14. Omel’yanovskii V. V., Avksent’eva M. V., Sura M. V., Khachatryan G. R., Fedyaeva V. K. Methodical recommendations for the evaluation of the comparative clinical efficacy and safety of the medicinal product [Metodicheskie rekomendatsii po otsenke sravnitel’noi klinicheskoi effektivnosti i bezopasnosti lekarstvennogo preparata (in Russian)]. Moscow. 2016; 58 s.

15. Omel’yanovskii V. V., Avksent’eva M. V., Sura M. V., Gerasimova K. V., Dzanaeva A. V. Methodical recommendations for assessing the impact on the budget in the framework of the program of state guarantees for free provision of medical care to citizens [Metodicheskie rekomendatsii po otsenke vliyaniya na byudzhet v ramkakh realizatsii programmy gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi (in Russian)]. Moscow. 2016; 28 s.

16. Starkie H. J., Briggs A. H., Chambers M. G., Jones P. Predicting EQ-5D values using the SGRQ. Value Health. 2011; 14 (2): 354-60.

17. Maleki-Yazdi M. R., Kaelin T., Richard N. et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014 Dec; 108 (12): 1752-60.

18. Anoro Ellipta. Instructions for medical use. State Drug Register [Instruktsiya po meditsinskomu primeneniyu. Gosudarstvennyi reestr Lekarstvennykh Sredstv (in Russian)]. URL: www.grls.rosminzdrav.ru. Accessed: 15.12.2016.

19. Spiriva Respimat. Instructions for medical use. State Drug Register [Instruktsiya po meditsinskomu primeneniyu. Gosudarstvennyi reestr Lekarstvennykh Sredstv (in Russian)]. URL: www.grls.rosminzdrav.ru. Accessed: 15.12.2016.

20. Global strategy for diagnosis, treatment and prevention of chronic obstructive pulmonary disease (revision 2014) / Trans. With English. Ed. A. S. Belevsky [Global’naya strategiya diagnostiki, lecheniya i profilaktiki khronicheskoi obstruktivnoi bolezni legkikh (peresmotr 2014 g.) / Per. s angl. pod red. A. S. Belevskogo (in Russian)]. Moscow. 2014; 92 s.

21. Chronic obstructive pulmonary disease. Clinical recommendations [Khronicheskaya obstruktivnaya bolezn’ legkikh. Klinicheskie rekomendatsii (in Russian)]. Moscow. 2016; 69 s.

22. Makarova E. V., Shumilova S. V., Vakhlamov V. A., Kasatova E. S., Menkov N. V., Lukovnikova N. B., Varvarina G. N., Tyurikova L. V., Karaulov A. V., Novikov V. V. Effect of noninvasive ventilation on functional and immune parameters in patients with severe exacerbation of chronic obstructive pulmonary disease. [Vliyanie neinvazivnoj ventilyacii legkih na funkcional’nye i immunnye pokazateli u bol’nyh s tyazhelym obostreniem hronicheskoj obstruktivnoj bolezni legkih]. Klinicheskaya Medicina. 2017; 95 (4): 344-349 (in Russian).

23. Makarova E. V., Varvarina G. N., Menkov N. V., Tsapaeva M. Yu., Lazareva E. S., Kazatskaya Zh. A., Novikov V. V., Karaulov A. V. Nebulized budesonide in the treatment of exacerbations of chronic obstructive pulmonary disease: efficacy, safety and effect on the content of soluble differentiation molecules in serum. [Nebulizirovannyj budesonid v lechenii obostrenij hronicheskoj obstruktivnoj bolezni legkih: ehffektivnost’, bezopasnost’ i vliyanie na soderzhanie rastvorimyh differencirovochnyh molekul v syvorotke krovi]. Terapevticheskij arhiv. 2016; 88 (3): 24-31 (in Russian).


For citation:


Kosolapov E.G., Kochenkov F.S., Pogudina N.L., Blinov D.V. COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2017;10(2):31-40. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.2.031-040

Views: 176


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)